Key clinical point: Rituximab plus lenalidomide was as effective as rituximab with chemotherapy but with a different safety profile.
Major finding: Complete responses were seen in 48% of rituximab/lenalidomide patients versus 53% in the rituximab/chemotherapy patients (P = .13).
Study details: A phase 3 superiority trial of 1,030 patients with previously untreated follicular lymphoma.
Disclosures: Celgene and the Lymphoma Academic Research Organization funded the study. The authors reported various disclosures, including financial ties to Celgene.
Morschhauser F et al. N Engl J Med. 2018;379:934-47.
This Week's Must Reads
Study examines rehabilitative palliative care in cancer, Nottelmann L et al. 2018 Palliative and Supportive Care in Oncology Symposium Abstract 75
HSCT performs well in scleroderma-related lung disease, Goldin J et al. Arthritis Rheumatol. 2018;70(Suppl 10): Abstract 901
Phase 2 results for combo therapy in relapsed AML, Daver N et al. Cancer Discov. 2018 Nov 8. doi: 10.1158/2159-8290.CD-18-0774
RNA editing contributes to myeloma pathogenesis, Teoh PJ et al. Blood. 2018;132(12):1304-17
Transcription factor networks in AML, Assi SA et al. Nat Genet. 2018 Nov 12. doi: 10.1038/s41588-018-0270-1
Must Reads in Indolent Lymphoma
BTK inhibitor shows phase 1 results in Waldenstrom’s macroglobulinemia, Leukemia & Lymphoma 2018
The role of PTPN22 R620W in CLL, Leukemia & Lymphoma 2018
Ibrutinib dosing changes and the impact on survival, Williams AM et al. Clin Lymphoma Myeloma Leuk. 2018 Oct 12. doi: 10.1016/j.clml.2018.10.005
Throly system predicts thromboprophylaxis in lymphoma patients, Leukemia and Lymphoma 2018, Dubrovnik, Croatia
Long-term data on chemo-free approach in advanced indolent lymphoma, Lockmer S et al. J Clin Oncol. 2018 Oct 4:JCO1800262. doi: 10.1200/JCO.18.00262